Circulatory Astrocyte and Neuronal EVs as Potential Biomarkers of Neurological Dysfunction in HIV-Infected Subjects and Alcohol/Tobacco Users

Diagnosis of central nervous system (CNS) complications associated with HIV, alcohol, and tobacco typically requires expensive neuroimaging or invasive lumbar punctures for cerebrospinal fluid (CSF). This study investigated whether extracellular vesicles (EVs)—small, transportable particles shed by cells—circulating in the blood could serve as accessible, noninvasive biomarkers for neurological dysfunction in these populations.

The researchers recruited 23 participants and categorized them into groups, including healthy controls, HIV-positive individuals, and substance users (alcohol drinkers and tobacco smokers). They isolated EVs from participants' plasma and validated them using transmission electron microscopy (TEM) and other standard characterization techniques. They then used Western blotting to measure the expression of two specific proteins: Glial Fibrillary Acidic Protein (GFAP), a marker of astrocyte activation, and L1 Cell Adhesion Molecule (L1CAM), a marker for neuronal integrity.

The analysis revealed that GFAP expression was significantly higher in plasma EVs from both HIV-positive individuals and alcohol consumers compared to healthy controls, suggesting that these conditions lead to astrocyte activation. Furthermore, L1CAM expression was significantly elevated in cigarette smokers, potentially indicating neuronal injury. Interestingly, the study found no additive effect on these markers in HIV-positive individuals who also consumed alcohol or smoked, suggesting these pathways might already be saturated by the underlying HIV infection or the substances themselves.

Because EVs can cross the blood-brain barrier, they provide a window into CNS-specific pathological processes through a simple blood draw. Identifying that GFAP and L1CAM are packaged within these EVs and respond to HIV, alcohol, and tobacco use offers a promising, cost-effective alternative for monitoring brain health in vulnerable populations. This could eventually allow for earlier detection of neurocognitive disorders without the physical or financial burden of traditional diagnostic methods.